Canos
Canos is a YC Fall 2026 (F26) company. Based in Oxford, England, United Kingdom.
About Canos
Summary
Canos builds a liquid biopsy platform that detects cancer in dogs from a single blood draw, sequencing cell-free DNA to analyze fragmentation, copy number variation, and methylation signals. Healthy dogs get a genomic baseline banked at the time of testing, updated annually to track any emerging signals. Dogs already diagnosed with cancer use a separate monitoring product to follow molecular changes through treatment.
Business model
$699 per test, including the vet visit
Go-to-market
Dog owners purchase tests directly, with mobile vets and vet clinics handling the blood draw; Canos currently serves San Francisco and New York City through those veterinary partners.
From the Y Combinator listing
AI-powered blood test to detect cancer in dogs (and cats soon).
Canos is bringing a human-grade liquid biopsy platform for dogs, starting with a single blood draw. We sequence cell-free DNA to perform multi-modal analysis of fragmentation, copy number variation, native methylation (5mC and 5hmC) and more to detect cancer signals. Owners bank a healthy baseline for their dog and track changes every year. Dogs already diagnosed get personalized monitoring through treatment. We partner with mobile vets and vet clinics to serve SF and NYC. Our mission is to make pet cancer curable through early detection and monitoring.
Facts
- Healthcare / Healthcare -> Diagnostics
- Oxford, England, United Kingdom
- Active
- Early
Founders (1)
- Ming-shan Tsai
Score every batch against your own thesis
GPAgent's sourcing agent reads every company in a batch, scores each one against your fund's thesis in a private workspace, and lines up the founders worth meeting before Demo Day. You decide who to contact. Your scores, notes, and pipeline never appear on these pages.
How Accelerator intelligence works